Resources
Home
/
Resources
-
Strategies and Challenges for Setting Specifications for MAM in Relation to Conventional CE Methods
Roundtable 3 Notes: CE Pharm 2021
-
New CE Modalities- How to Analyze Complex Biomolecules
Roundtable 2 Notes: CE Pharm 2021
-
CE Training Best Practices including Neutral Coated Capillaries Pros and Pitfalls: Going Beyond the mAb Separations
Roundtable 1 Notes: CE Pharm 2021
-
Validation
Roundtable 10 Notes: CE Pharm 2020
-
DOE and QbD
Roundtable 9 Notes: CE Pharm 2020
-
Can We Go Any Faster with CE Automation?
Roundtable 8 Notes: CE Pharm 2020
-
CE Method Lifecycle Management
Roundtable 7 Notes: CE Pharm 2020
-
Integration of Electropherograms
Roundtable 6 Notes: CE Pharm 2020
-
Collaborations and Instrumentation Development
Roundtable 5 Notes: CE Pharm 2020
-
Peak ID
Roundtable 4 Notes: CE Pharm 2020
-
New Modalities
Roundtable 3 Notes: CE Pharm 2020
-
Novel Technologies
Roundtable 2 Notes: CE Pharm 2020
-
Troubleshooting Capillary Electrophoresis Instrumentation and Separations
Roundtable 1 Notes: CE Pharm 2020
-
Status of Biotherapeutic Therapies for COVID-19
Roundtable 40 Notes: WCBP 2021
-
Core Analytical ICH Topics & Their Impact ICH Q6, Q2/14
Roundtable 38 Notes: WCBP 2021
-
Challenges in Meeting Global Pharmacopoeia Requirements - Strategies to Harmonize
Roundtable 37 Notes: WCBP 2021
-
Practical Considerations for Implementing ICH Q14 for Each Drug Modality – Old and New
Roundtable 36 Notes: WCBP 2021
-
Structure Function Studies of Non-standard mAb and Protein Therapeutics
Roundtable 34 Notes: WCBP 2021
-
Multi-Attribute Method - Challenges in using MAM for QC of Therapeutic Proteins
Roundtable 33 Notes: WCBP 2021
-
Visible and Sub-visible Particles: Practical Experiences in Manufacturing Support and Quality Control
Roundtable 32 Notes: WCBP 2021